Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | CAD | P27708 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9190299 | 0.79 | ALDH1A1 (0.42) | GRIK1GRIK2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL27584239 | 0.79 | ALOX15 (0.41) | CYP2D6CYP2C19CYP2C9ALDH1A1LMNA | |
| SCHEMBL1770516 | 0.78 | GRIK1 (0.41) | GRIK1GRIK2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL1274021 | 0.78 | GRIK1 (0.41) | GRIK1GRIK2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL10837285 | 0.78 | ALDH1A1 (0.41) | GRIK1GRIK2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL18571419 | 0.78 | GRIK1 (0.41) | GRIK1GRIK2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL13979544 | 0.76 | GRIK1 (0.53) | GRIK1GRIK2ALOX15 | |
| SCHEMBL7694807 | 0.76 | LMNA (0.39) | GRIK1GRIK2CYP2D6CYP2C19CYP2C9 | |
| Hydrochloric Acid SCHEMBL3620844 | 0.76 | GRIK1 (0.40) | GRIK1GRIK2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL28127614 | 0.76 | ALDH1A1 (0.39) | GRIK1GRIK2CYP2D6CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-4161902-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021252644-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-7301022-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7301022-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7301022-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-11-27 | — | — | US | disclosed |
| WO-2006089311-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | GRIK1 472/4885GRIK2 392/4885CYP2D6 2008/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | GRIK1 4299/4885GRIK2 4003/4885CYP2D6 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.